Righton
Genetic engineering technology company based in Shanghai.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
Shanghai Rightongene Biotechnology Co., Ltd. (Righton), established in February 2012, operates as a life science enterprise centered on the research, development, production, and sales of in vitro diagnostic products. The company was founded by Chairman and General Manager, Xiong Hui. Righton concentrates on delivering diagnostic products and services for oncology, specifically for tumor classification, MRD (Minimal Residual Disease) monitoring, and early tumor screening. The firm went public on May 17, 2021.
Righton's business model encompasses the entire lifecycle of in vitro diagnostic solutions, from initial R&D to sales and subsequent scientific and testing services. This positions the company to serve the precision medicine market. Revenue is generated through the sale of its diagnostic kits and instruments, as well as providing medical testing services. The company's financial data indicates a trailing 12-month revenue of $32.3 million as of March 2025.
The company's product portfolio is extensive, featuring a range of diagnostic kits for various conditions. Key products include leukemia-related fusion gene detection kits, immunoglobulin gene rearrangement test kits, and several gene mutation test kits for cancers, such as EGFR, K-ras, and Braf. Additionally, Righton offers diagnostic kits for infectious diseases like rubella and herpes simplex virus. A notable product is the RightOn Cancer Sequencing Kit, which enables comprehensive profiling of over 1,000 cancer genes from a single test. This kit is designed for high specificity and sensitivity, capable of detecting variants as low as 5% in tumor samples and working effectively with low DNA input. The company also produces and sells medical instruments, including automated sample processing and nucleic acid extraction systems.
Keywords: molecular diagnostics, in vitro diagnostics, oncology testing, precision medicine, gene detection, cancer sequencing, leukemia diagnostics, MRD monitoring, tumor screening, liquid biopsy, diagnostic reagents, automated nucleic acid extraction, EGFR mutation testing, K-ras mutation testing, clinical diagnostics, life sciences, biotechnology, cancer research, genomic testing, diagnostic services